Abstract
The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin receptors are common in cancer cells resulting in alteration of the ability of malignant cells to interact with the extracellular matrix, and promoting migration as well as facilitating survival outside the tumour normal environment. β integrins are potentially involved in every step of the metastatic process and expression of both αρ β and α β is correlated with metastatic ability of tumour cells. The recognition of the RGD binding motif common to the disintegrins and natural integrin ligands such as fibrinogen allowed the development of small molecule β integrin antagonists, progressing from linear peptides containing the RGD sequence to cyclic peptides with well-defined conformation, and hence to small molecule peptidomimetics with improved pharmacological properties. In this review, we summarize the role of the β -subfamily of integrins when expressed in normal and tumour tissue, the development of small-molecule antagonists of β integrins and their potential anti-cancer applications.
Keywords: β, integrin, cancer, metastasis, RGD peptidomimetic
Current Cancer Drug Targets
Title: Function and Antagonism of β Integrins in the Development of Cancer Therapy
Volume: 9 Issue: 4
Author(s): H. M. Sheldrake and L. H. Patterson
Affiliation:
Keywords: β, integrin, cancer, metastasis, RGD peptidomimetic
Abstract: The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin receptors are common in cancer cells resulting in alteration of the ability of malignant cells to interact with the extracellular matrix, and promoting migration as well as facilitating survival outside the tumour normal environment. β integrins are potentially involved in every step of the metastatic process and expression of both αρ β and α β is correlated with metastatic ability of tumour cells. The recognition of the RGD binding motif common to the disintegrins and natural integrin ligands such as fibrinogen allowed the development of small molecule β integrin antagonists, progressing from linear peptides containing the RGD sequence to cyclic peptides with well-defined conformation, and hence to small molecule peptidomimetics with improved pharmacological properties. In this review, we summarize the role of the β -subfamily of integrins when expressed in normal and tumour tissue, the development of small-molecule antagonists of β integrins and their potential anti-cancer applications.
Export Options
About this article
Cite this article as:
Sheldrake M. H. and Patterson H. L., Function and Antagonism of β Integrins in the Development of Cancer Therapy, Current Cancer Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/156800909788486713
DOI https://dx.doi.org/10.2174/156800909788486713 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Coumarin Hybrids: Promising Scaffolds in the Treatment of Breast Cancer
Mini-Reviews in Medicinal Chemistry Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein
Current Cancer Therapy Reviews 1,3,4-Thiadiazole Based Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment
Current Medicinal Chemistry Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Retraction Note: Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer
Current Pharmaceutical Biotechnology Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry Chemical and Biological Approaches for Mycotoxin Control: A Review
Recent Patents on Food, Nutrition & Agriculture Evidence for Epigenetic Alterations in Turner Syndrome Opens up Feasibility of New Pharmaceutical Interventions
Current Pharmaceutical Design Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science